# Safety and Efficacy of OTL78 (Zopocianine)

> **NCT07725523** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Clinton Bahler** · enrollment: 36 (estimated)

## Conditions studied

- Prostate Cancer Surgery
- Prostate Cancer Metastatic Disease

## Interventions

- **DRUG:** 0.06mg/kg ZOPOCIANINE given 1-7 days prior to surgery

## Key facts

- **NCT ID:** NCT07725523
- **Lead sponsor:** Clinton Bahler
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-07
- **Final completion:** 2027-09
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-09-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725523, "Safety and Efficacy of OTL78 (Zopocianine)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07725523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*